 BOSTON--BUSINESS WIRE--- KRTX--Karuna Therapeutics, Inc. NASDAQ: KRTX, a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and year ended 2020 and provided a general business update. This past year was foundational for Karuna. We realized significant milestones and achievements including the initiation of the first Phase 3 trial in ou 